ClinicalTrials.gg
CompletedNCT00402987Updated Mar 3, 2021Results posted

Testing The Effectiveness Of Celecoxib In Patients With Painful Sore Throat

A Phase 3 interventional study of Celecoxib and Celecoxib in Pharyngitis, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
269
Allocation
Randomized
Ages
18 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Pharyngitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Pharyngitis · United States.

Enrollment
15th of 35
269 · median 204
Started
2006
with 2 others
Phase 3
18 of 41
none open now
Registered
7th of 41
by date

Among the 41 studies in Pharyngitis with a site in United States, this one is the 15th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2006, is one of 18 in phase 3, and was the 7th registered.

Pharyngitis

227 studies on the registry are indexed under Pharyngitis; 36 are open to participants now.

Browse Pharyngitis studies →

Open to participants now

4 of the 41 studies in Pharyngitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Pharyngitis studies recruiting now, 5 (26%) set no upper age limit and 10 (53%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Pharyngitis with a site in United States, or all of them as a file.
02

Study summary

We are proposing a study in which we utilize and augment the sore throat pain model to assess the analgesic effectiveness of celecoxib compared to placebo in patients with painful pharyngitis under randomized, double-blind, placebo-controlled conditions.

03

Conditions studied

  • Pharyngitis

Keywords

  • sore throat
  • acute pain
04

Who can participate

Ages eligible
18 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient must have a diagnosis of pharyngitis with objective findings of tonsillo-pharyngitis.
  • The patient is willing to take "nothing by mouth" including inhaled treatments except trial medication during the two hours while at the site and following trial drug administration (e.g. not smoking, food, drink, candy, lozenges, chewing gum). The patient will be allowed food and drink between hours 2 and 24, but no other oral or inhaled treatments such as smoking, lozenges, chewing gum. After the two hour assessment, the patients will be allowed food and drink within one half-hour following any hourly evaluations sore throat.

Exclusion criteria

Exclusion Criteria:

  • The patient has used any analgesic/antipyretic within 1 dosing interval preceding administration of the first dose of trial medication.
  • The patient anticipates using any inhaled therapy including beta-agonists (e.g., ventolin) during the 24 hour trial period and, if used, has only used inhaled therapy on an intermittent basis in the week prior to the screening visit.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
269 participants (actual)

Study arms

  • Experimental
    celecoxib 50 mg/50 mg

    Drug: Celecoxib

  • Experimental
    celecoxib 100 mg/placebo

    Drug: Celecoxib

  • Experimental
    celecoxib 100 mg/50 mg

    Drug: celecoxib

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg

  • dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo

  • dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg

  • Drugplacebo

    dose 1 placebo followed 6-12 hours later by dose 2 placebo

06

What researchers measure

Primary outcomes

  1. Sum of Sore Throat Pain Intensity Difference (SPID2) on Swallowing at 2 Hours Post-First Dose

    Based on the Pain Intensity scores measured on a Visual Analogue Scale (PI-VAS: 0mm=no pain,100mm=worst possible pain), assessed by the subjects, the SPID2 is the area under the curve (AUC) over the 2-hour period post-first dose of the Pain Intensity Difference (PID) scores using the trapezoidal rule.

    Time frame: 2 hours Post-First Dose

Secondary outcomes

  1. Sore Throat Pain Intensity Difference (PID) Within 6 Hours Post-First Dose

    Pain intensity (PI) on Swallowing as Measured by PI-VAS scale: 0mm=no pain, 100mm=worst possible pain. Sore throat PID score was obtained by subtracting the PI at each time point from the Baseline PI score. Increase in scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.

    Time frame: Within First 6 hours Post-First Dose

  2. Sore Throat Pain Intensity Difference (PID) From 7 to 24 Hours Post-First Dose

    Pain intensity (PI) on Swallowing as Measured by PI-VAS scale: 0mm=no pain, 100mm=worst possible pain. PID score was obtained by subtracting the PI at each time point from the Baseline PI score. An increase in scores indicated a lessening of subjects' pain as compared to Baseline scores, thus, higher scores indicated a greater reduction in pain.

    Time frame: 7 to 24 hours

  3. Sum of Sore Throat Pain Intensity Difference (SPID) Within 6 Hours Post-First Dose

    The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The PID \[based on PI-VAS scale: 0mm=no pain, 100mm=worst possible pain\] was calculated as the difference between the pain intensity at the time and at baseline.

    Time frame: up to 6 hours

  4. Sum of Sore Throat Pain Intensity Difference (SPID) From 7 to 24 Hours Post-First Dose

    The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The PID \[based on PI-VAS scale: 0mm=no pain, 100mm=worst possible pain\] was calculated as the difference between the pain intensity at the time and at baseline.

    Time frame: 7 to 24 hours

  5. Sore Throat Relief Rating Scale (STRRS) Within 6 Hours Post-First Dose

    STRRS score (scale: 0 no relief to 6 complete relief); a higher pain score indicated a greater reduction in pain.

    Time frame: within the first 6 hours

  6. Sore Throat Relief Rating Scale (STRRS) From 7 to 24 Hours Post-First Dose

    STRRS score (scale: 0 no relief to 6 complete relief); a higher score indicated a greater reduction in pain.

    Time frame: 7 to 24 hours

  7. Sore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 6 Hours Post-First Dose

    Subjects Achieving at Least 'Moderate Relief' as Measured by STRRS (range: 0=no relief to 6=complete relief); Moderate relief is defined as STRRS = 3).

    Time frame: at 6 hours

  8. Sore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 12 Hours Post-First Dose

    Subjects Achieving at Least 'Moderate Relief' as Measured by STRRS (range: 0=no relief to 6=complete relief); Moderate relief is defined as STRRS = 3).

    Time frame: 12 hours

  9. Time to Perceptible Pain Relief

    Defined as time (measured by stopwatch) when subject began to feel any pain relieving effect from the drug

    Time frame: Within 2 Hours Post-First Dose

  10. Time to Meaningful Pain Relief

    The time (measured by stopwatch) when the subject felt their pain relief was meaningful to them was not estimable thus the number of subjects experiencing meaningful pain relief within 2 hours of first dose is reported

    Time frame: Within 2 Hours Post-First Dose

  11. Time to Onset of Analgesia

    Equal to time of perceptible pain relief when both perceptible pain relief and meaningful pain relief were experienced- the median time was not estimable thus the number of subjects with onset of analgesia within 2 hours of first dose is reported

    Time frame: Within 2 Hours Post-First Dose

  12. Patient's Global Evaluation of Study Medication at 6 Hours Post-First Dose

    Subject assessment of overall impression of study drug on 4 point scale from 1 (poor) to 4 (excellent)

    Time frame: 6 Hours Post-First Dose

  13. Patient's Global Evaluation of Study Medication at 12 and 24 Hours Post-First Dose

    Subject assessment of overall impression of study drug on 4 point scale from 1 (poor) to 4 (excellent)

    Time frame: 12 and 24 hours Post-First Dose

Other outcomes

  1. Throat Soreness Scale (TSS) Difference Within 6 Hours Post-First Dose

    The Pain Intensity Difference (PID) based on TSS (scale: 0=not sore to 10=very sore) was calculated as the difference between the pain intensity at the time and at baseline.

    Time frame: Within first 6 hours post-first dose

  2. Throat Soreness Scale (TSS) Difference From 7 to 24 Hours Post-First Dose

    The Pain Intensity Difference (PID) based on TSS (scale: 0=not sore to 10=very sore) was calculated as the difference between the pain intensity at the time and at baseline.

    Time frame: 7 to 24 hours post-first dose

  3. Sore Throat Pain Intensity Difference (SPID2) as Measured by Throat Soreness Scale (TSS) at 2 Hours Post-First Dose

    SPID2 was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS scale: 0=not sore to 10=very sore) at 2 hours post dose and at baseline.

    Time frame: 2 hour period Post-First Dose

  4. Sum of Throat Soreness Difference as Measured by Throat Soreness Scale (TSS) Within 6 Hours Post-First Dose

    The sum of sore throat pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS range: 0=not sore to 10=very sore) at the time and at baseline.

    Time frame: Within 6 hours Post-First Dose

  5. Sum of Throat Soreness Difference as Measured by Throat Soreness Scale (TSS) From 7 to 24 Hours Post-First Dose

    The sum of sore throat pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS range: 0=not sore to 10=very sore) at the time and at baseline.

    Time frame: 7 to 24 hours Post-First Dose

  6. Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) Within 6 Hours Post-First Dose

    The Difficulty Swallowing Pain Intensity Difference (PID) was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.

    Time frame: Within 6 hours Post-First Dose

  7. Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) From 7 to 24 Hours Post-First Dose

    The Difficulty Swallowing Pain Intensity Difference (PID) was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.

    Time frame: 7 to 24 hours Post-First Dose

  8. Sum of Sore Throat Pain Intensity Difference (SPID2) as Measured by Difficulty Swallowing Scale (DSS) at 2 Hours Post-First Dose

    SPID2 was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 2 hours post dose and at baseline.

    Time frame: Over 2 hour Period Post-First Dose

  9. Sum of Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) Within 6 Hours Post-First Dose

    The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.

    Time frame: Within 6 hours Post-First Dose

  10. Sum of Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) From 7 to 24 Hours Post-First Dose

    The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.

    Time frame: 7 to 24 hours Post-First Dose

  11. Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 6 Hours Post-First Dose

    Number of Subjects with \>= 50% Pain Intensity Difference (PID) on the DSS. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 6 hours and at baseline.

    Time frame: At 6 hours

  12. Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 12 Hours Post-First Dose

    Number of Subjects with \>= 50% Pain Intensity Difference (PID) on the DSS. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 12 hours and at baseline.

    Time frame: At 12 Hours

  13. Total Pain Relief (TOTPAR) at 2 and 6 Hours Post-First Dose

    TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief).

    Time frame: 2 and 6 hours Post-First Dose

  14. Total Pain Relief (TOTPAR) at 12 and 24 Hours Post-First Dose

    TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief).

    Time frame: 12 and 24 hours Post-First Dose

  15. Subjects With >= 50% Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose

    TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief). Maximum TOTPAR over 6 hours is 36. If the subject calculated TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject is said to have achieved \>=50% TOTPAR.

    Time frame: 6 hours Post-First Dose

  16. Subjects With >= 50% Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose

    TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief). Maximum TOTPAR over 12 hours is 72. If the subject calculated TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject is said to have achieved \>=50% TOTPAR.

    Time frame: 12 hours Post-First Dose

  17. Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose

    NNT is number of subjects needed to treat to have one extra subject report a 50% or better pain relief over 6 hours based on maximum possible pain relief on Sore Throat Relief Rating Scale. Maximum TOTPAR over 6 hours is 36. If the subject TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject has achieved \>=50% TOTPAR.

    Time frame: 6 hours Post-First Dose

  18. Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose

    NNT is number of subjects needed to treat to have one subject report a 50% or better pain relief over 12 hours based on maximum possible pain relief on Sore Throat Relief Rating Scale. Maximum TOTPAR over 12 hours is 72. If the subject TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject has achieved \>=50% TOTPAR.

    Time frame: 12 hours Post-First Dose

  19. Subjects With Sore Throat Pain at Least 35% Gone and at Least 50% Gone at 2 and 6 Hours Post-First Dose

    \>= 35% and 50% Pain Intensity Difference (PID) on the Pain Intensity-Visual Analog Scale (PI-VAS) (scale: 0mm=no pain, 100mm=worst possible pain). The PID was calculated as the difference between the pain intensity at the time and at baseline.

    Time frame: 2 and 6 hours Post-First Dose

  20. Subjects With Sore Throat Pain at Least 35% Gone and at Least 50% Gone at 12 Hours Post-First Dose

    \>= 35% and 50% Pain Intensity Difference (PID) on the Pain Intensity-Visual Analog Scale (PI-VAS) (scale: 0mm=no pain, 100mm=worst possible pain). The PID was calculated as the difference between the pain intensity at 12 hours and at baseline.

    Time frame: 12 hours Post-First Dose

  21. Subjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 2 and 6 Hours Post-First Dose

    Symptom relief measured as self-directed endpoints defined by each individual at end of study using Sore Throat Relief Rating Scale (STRRS); STRRS score ranges from 0=no relief to 6=complete relief. If subject scored same or greater in their STRRS during the study then they achieved their 'Meaningful Relief' or 'Much Improvement'.

    Time frame: 2 and 6 hours Post-First Dose

  22. Subjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 12 Hours Post-First Dose

    Symptom relief measured as self-directed endpoints defined by each individual at end of study using Sore Throat Relief Rating Scale (STRRS); STRRS score ranges from 0=no relief to 6=complete relief. If subject scored same or greater in their STRRS during the study then they achieved their 'Meaningful Relief' or 'Much Improvement'.

    Time frame: 12 hours Post-First Dose

  23. Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Who Had Perceptible Relief Onset Time Within 1 Hour

    At end of study subjects defined meaningful pain relief by completing Meaningful Relief Scale. Meaningful relief was achieved if Sore Throat Relief Rating Scale (STRRS) score (range: 0=no relief to 6=complete relief) at end of the study was the same or higher than individually defined relief score during the study. Perceptible relief is STRRS \>0.

    Time frame: Within 6 hours Post-First Dose

  24. Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Who Still Had Perceptible Relief at 12 and 24 Hours Post-First Dose

    At end of study subjects defined meaningful pain relief by completing the Meaningful Relief Scale. Meaningful relief was achieved if Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief) score at end of the study was the same or higher than individually defined relief score during the study. Perceptible relief is STRRS \>0

    Time frame: 12 and 24 hours Post-First Dose

  25. Median Onset Time of First Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose

    Perceptible Relief is score \>0 on STRRS. Individual level of meaningful relief had to be reached within 6 hours. Meaningful Relief was achieved if Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief)score at the end of the study was the same or higher than individually defined meaningful relief score during the study.

    Time frame: 24 Hours

  26. Median Offset Time of No Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose

    Offset time is time of first no perceptible relief (STRRS score=0) with meaningful relief (score\>0) at earlier time. STRRS score ranges from 0=no relief to 6=complete relief.

    Time frame: 24 Hours

  27. Treatment Failures on STRRS Questionnaire

    Subjects were considered treatment failures if all of the STRRS scores were less than each individual's 'meaningful relief' scores. STRRS score ranges from 0=no relief to 6=complete relief.

    Time frame: 24 hours Post-First Dose

  28. Subjects Taking Rescue Medication

    Subjects were allowed to use rescue medication at any time during the trial, but were discouraged from taking rescue medication within 2 hours of administration of the first dose of study drug.

    Time frame: Within 24 hours Post-First Dose

  29. Treatment Satisfaction Questionnaire for Medication (TSQM vII)

    11 questions scored on factors: effectiveness, side effects, convenience, overall satisfaction. TSQM vII scores range 0 to 100, with higher scores indicating a higher level of global satisfaction with treatment.

    Time frame: 24 hours or immediately prior to taking rescue medication

  30. First Perceptible Relief

    Subjects having First Perceptible Relief at each time point. Perceptible relief is score \>0 on Sore Throat Relief Rating Scale(STRRS)(range: 0=no relief to 6=complete relief).

    Time frame: up to 24 hours

  31. No Perceptible Relief

    Subjects having No Perceptible Relief at each time point. No Perceptible relief is score = 0 on Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief).

    Time frame: up to 24 hours

07

Results

Posted Mar 12, 2009

Participant flow

1 center in the United States.

Participant flow — Overall Study
MilestoneCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
Started90454589
Completed90454489
Not completed0010
Withdrew: Lack of efficacy0010

Outcome measures

PrimarySum of Sore Throat Pain Intensity Difference (SPID2) on Swallowing at 2 Hours Post-First Dose

Based on the Pain Intensity scores measured on a Visual Analogue Scale (PI-VAS: 0mm=no pain,100mm=worst possible pain), assessed by the subjects, the SPID2 is the area under the curve (AUC) over the 2-hour period post-first dose of the Pain Intensity Difference (PID) scores using the trapezoidal rule.

Time frame:
2 hours Post-First Dose
Reported as:
Least squares mean · units on a scale * hours
Sum of Sore Throat Pain Intensity Difference (SPID2) on Swallowing at 2 Hours Post-First Dose
units on a scale * hoursCelecoxib 100mg (Pooled)Placebo
Sum of Sore Throat Pain Intensity Difference (SPID2) on Swallowing at 2 Hours Post-First Dose21.0 ± 2.209.4 ± 2.21
Statistical analysis
  • Celecoxib 100mg (Pooled) vs Placebo · generalized linear model · p = 0.0003 · Mean difference (final values): 11.7 · 95% CI 5.5 to 17.9p-value was calculated using Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
SecondarySore Throat Pain Intensity Difference (PID) Within 6 Hours Post-First Dose

Pain intensity (PI) on Swallowing as Measured by PI-VAS scale: 0mm=no pain, 100mm=worst possible pain. Sore throat PID score was obtained by subtracting the PI at each time point from the Baseline PI score. Increase in scores indicated a lessening of subjects' pain compared to baseline scores; higher scores indicated a greater reduction in pain.

Time frame:
Within First 6 hours Post-First Dose
Reported as:
Least squares mean · units on a scale
Sore Throat Pain Intensity Difference (PID) Within 6 Hours Post-First Dose
units on a scaleCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
15 min1.62 ± 0.641.92 ± 0.640.40 ± 0.64
30 min4.70 ± 0.904.93 ± 0.902.14 ± 0.91
45 min9.57 ± 1.227.05 ± 1.233.85 ± 1.24
60 min12.18 ± 1.4711.43 ± 1.475.34 ± 1.48
75 min17.24 ± 1.6213.24 ± 1.626.60 ± 1.64
90 min22.39 ± 1.8817.00 ± 1.886.75 ± 1.90
1.75 hours24.68 ± 1.9918.80 ± 1.997.41 ± 2.01
2 hours26.63 ± 2.1921.51 ± 2.198.06 ± 2.21
3 hours27.90 ± 2.2922.21 ± 2.299.06 ± 2.31
4 hours25.52 ± 2.3123.15 ± 2.3110.35 ± 2.33
5 hours24.12 ± 2.2623.56 ± 2.2610.47 ± 2.28
6 hours21.42 ± 2.2420.59 ± 2.249.04 ± 2.26
Statistical analysis
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.212 (Analysis at 15 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.056 (Analysis at 30 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.005 (Analysis at 45 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.002 (Analysis at 60 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 75 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 90 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 1.75 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 2 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 3 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 4 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 5 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 6 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
SecondarySore Throat Pain Intensity Difference (PID) From 7 to 24 Hours Post-First Dose

Pain intensity (PI) on Swallowing as Measured by PI-VAS scale: 0mm=no pain, 100mm=worst possible pain. PID score was obtained by subtracting the PI at each time point from the Baseline PI score. An increase in scores indicated a lessening of subjects' pain as compared to Baseline scores, thus, higher scores indicated a greater reduction in pain.

Time frame:
7 to 24 hours
Reported as:
Least squares mean · units on a scale
Sore Throat Pain Intensity Difference (PID) From 7 to 24 Hours Post-First Dose
units on a scaleCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
7 hours20.82 ± 2.3022.01 ± 3.2618.34 ± 3.259.32 ± 2.33
8 hours20.39 ± 2.2920.81 ± 3.2419.93 ± 3.238.12 ± 2.31
9 hours21.39 ± 2.3619.18 ± 3.3518.87 ± 3.339.92 ± 2.38
10 hours21.26 ± 2.4018.02 ± 3.4018.06 ± 3.399.56 ± 2.42
11 hours19.65 ± 2.4017.43 ± 3.4018.99 ± 3.399.29 ± 2.43
12 hours19.01 ± 2.5015.01 ± 3.5420.22 ± 3.528.60 ± 2.52
24 hours18.43 ± 2.5816.50 ± 3.6619.44 ± 3.6512.81 ± 2.61
Statistical analysis
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized Linear Model · p = 0.001 (Analysis at 7 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 8 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.006 (Analysis at 9 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.007 (Analysis at 10 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.014 (Analysis at 11 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.012 (Analysis at 12 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.365 (Analysis at 24 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
SecondarySum of Sore Throat Pain Intensity Difference (SPID) Within 6 Hours Post-First Dose

The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The PID \[based on PI-VAS scale: 0mm=no pain, 100mm=worst possible pain\] was calculated as the difference between the pain intensity at the time and at baseline.

Time frame:
up to 6 hours
Reported as:
Least squares mean · units on a scale * hours
Sum of Sore Throat Pain Intensity Difference (SPID) Within 6 Hours Post-First Dose
units on a scale * hoursCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
15 min0.2 ± 0.10.2 ± 0.10.1 ± 0.1
30 min1.0 ± 0.21.1 ± 0.20.4 ± 0.2
45 min2.8 ± 0.42.6 ± 0.41.1 ± 0.5
60 min5.5 ± 0.74.9 ± 0.72.3 ± 0.7
75 min9.2 ± 1.08.0 ± 1.03.8 ± 1.0
90 min14.1 ± 1.411.8 ± 1.45.4 ± 1.4
1.75 hours20.0 ± 1.816.2 ± 1.87.2 ± 1.8
2 hours26.4 ± 2.321.3 ± 2.39.1 ± 2.3
3 hours53.7 ± 4.343.1 ± 4.317.7 ± 4.4
4 hours80.4 ± 6.565.8 ± 6.527.4 ± 6.5
5 hours105.2 ± 8.589.2 ± 8.537.8 ± 8.6
6 hours128.0 ± 10.5111.2 ± 10.547.6 ± 10.6
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Generalized Linear Model · p = 0.180 (Analysis at 15 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.069 (Analysis at 30 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.010 (Analysis at 45 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.002 (Analysis at 60 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 75 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 90 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 1.75 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 3 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 4 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 5 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.096 (Analysis at 15 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.034 (Analysis at 30 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.022 (Analysis at 45 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.010 (Analysis at 60 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.005 (Analysis at 75 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.002 (Analysis at 90 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.001 (Analysis at 1.75 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 3 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 4 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 5 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.741 (Analysis at 15 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.759 (Analysis at 30 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.775 (Analysis at 45 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.561 (Analysis at 60 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.419 (Analysis at 75 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.237 (Analysis at 90 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.146 (Analysis at 1.75 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.113 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.086 (Analyaia at 3 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.111 (Analysis at 4 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.183 (Analysis at 5 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.259 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
SecondarySum of Sore Throat Pain Intensity Difference (SPID) From 7 to 24 Hours Post-First Dose

The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The PID \[based on PI-VAS scale: 0mm=no pain, 100mm=worst possible pain\] was calculated as the difference between the pain intensity at the time and at baseline.

Time frame:
7 to 24 hours
Reported as:
Least squares mean · units on a scale * hours
Sum of Sore Throat Pain Intensity Difference (SPID) From 7 to 24 Hours Post-First Dose
units on a scale * hoursCelecoxib 50mg/50mgCelecoxib 100 mg / PlaceboCelecoxib 100mg / 50mgPlacebo
7 hours149.2 ± 12.4151.8 ± 17.5111.6 ± 17.556.6 ± 12.5
8 hours169.8 ± 14.3173.2 ± 20.3130.8 ± 20.265.4 ± 14.5
9 hours190.7 ± 16.3193.2 ± 23.1150.2 ± 23.074.4 ± 16.5
10 hours212.0 ± 18.2211.8 ± 25.9168.6 ± 25.884.1 ± 18.4
11 hours232.4 ± 20.2229.5 ± 28.7187.2 ± 28.693.5 ± 20.5
12 hours251.8 ± 22.3245.7 ± 31.6206.8 ± 31.5102.5 ± 22.5
24 hours476.4 ± 48.7434.8 ± 69.0444.7 ± 68.8231.0 ± 49.2
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Placebo · Generalized linear model · p = 0.017 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.011 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.009 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.008 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.008 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.008 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.008 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.012 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo · Generalized linear model · p = 0.904 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo · Generalized linear model · p = 0.891 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo · Generalized linear model · p = 0.929 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo · Generalized linear model · p = 0.994 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo · Generalized linear model · p = 0.933 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo · Generalized linear model · p = 0.876 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo · Generalized linear model · p = 0.622 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.081 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.117 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.152 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.171 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.197 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.244 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.708 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.106 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.140 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.188 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.239 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.297 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.383 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg · Generalized linear model · p = 0.919 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100 mg / Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
SecondarySore Throat Relief Rating Scale (STRRS) Within 6 Hours Post-First Dose

STRRS score (scale: 0 no relief to 6 complete relief); a higher pain score indicated a greater reduction in pain.

Time frame:
within the first 6 hours
Reported as:
Least squares mean · scores on a scale
Sore Throat Relief Rating Scale (STRRS) Within 6 Hours Post-First Dose
scores on a scaleCelecoxib 50mg/50mgCelecoxib 100 mg (Pooled)Placebo
15 min0.12 ± 0.040.09 ± 0.040.16 ± 0.04
30 min0.41 ± 0.070.34 ± 0.070.34 ± 0.07
45 min0.74 ± 0.090.69 ± 0.090.52 ± 0.09
60 min1.22 ± 0.121.01 ± 0.120.64 ± 0.12
75 min1.58 ± 0.131.27 ± 0.130.79 ± 0.14
90 min1.88 ± 0.151.61 ± 0.150.88 ± 0.15
1.75 hours2.10 ± 0.161.74 ± 0.160.93 ± 0.16
2 hours2.22 ± 0.171.93 ± 0.170.92 ± 0.17
3 hours2.13 ± 0.171.92 ± 0.170.92 ± 0.17
4 hours2.08 ± 0.171.96 ± 0.171.10 ± 0.17
5 hours2.00 ± 0.171.97 ± 0.171.07 ± 0.17
6 hours1.81 ± 0.171.86 ± 0.170.96 ± 0.17
Statistical analysis
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = 0.537 (Analysis at 15 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = 0.697 (Analysis at 30 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = 0.203 (Analysis at 45 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = 0.003 (Analysis at 60 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 75 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 90 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 1.75 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 2 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 3 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 4 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 5 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 6 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
SecondarySore Throat Relief Rating Scale (STRRS) From 7 to 24 Hours Post-First Dose

STRRS score (scale: 0 no relief to 6 complete relief); a higher score indicated a greater reduction in pain.

Time frame:
7 to 24 hours
Reported as:
Least squares mean · scores on a scale
Sore Throat Relief Rating Scale (STRRS) From 7 to 24 Hours Post-First Dose
scores on a scaleCelecoxib 50mg/50mgCelecoxib 100 mg / PlaceboCelecoxib 100mg / 50mgPlacebo
7 hours1.71 ± 0.172.00 ± 0.241.67 ± 0.240.93 ± 0.17
8 hours1.68 ± 0.171.80 ± 0.241.71 ± 0.240.97 ± 0.17
9 hours1.69 ± 0.171.76 ± 0.251.56 ± 0.251.08 ± 0.17
10 hours1.74 ± 0.171.67 ± 0.251.51 ± 0.251.08 ± 0.18
11 hours1.67 ± 0.181.58 ± 0.251.60 ± 0.251.10 ± 0.18
12 hours1.56 ± 0.181.42 ± 0.251.53 ± 0.251.07 ± 0.18
24 hours1.69 ± 0.191.62 ± 0.271.60 ± 0.271.31 ± 0.19
Statistical analysis
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.001 (Analysis at 7 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.005 (Analysis at 8 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.046 (Analysis at 9 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.046 (Analysis at 10 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.111 (Analysis at 11 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.226 (Analysis at 12 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg vs Placebo · Generalized linear model · p = 0.537 (Analysis at 24 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
SecondarySore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 6 Hours Post-First Dose

Subjects Achieving at Least 'Moderate Relief' as Measured by STRRS (range: 0=no relief to 6=complete relief); Moderate relief is defined as STRRS = 3).

Time frame:
at 6 hours
Reported as:
Number · subjects
Sore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 6 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100 mg (Pooled)Placebo
Sore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 6 Hours Post-First Dose283113
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.010 (Treatment as a factor) · Odds ratio (or): 2.64 · 95% CI 1.3 to 5.5
  • Celecoxib 100 mg (Pooled) vs Placebo · Regression, Logistic · p = 0.003 (Treatment as a factor) · Odds ratio (or): 3.07 · 95% CI 1.5 to 6.4
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) · Regression, Logistic · p = 0.634 (Treatment as a factor) · Odds ratio (or): 1.16 · 95% CI 0.6 to 2.2
SecondarySore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 12 Hours Post-First Dose

Subjects Achieving at Least 'Moderate Relief' as Measured by STRRS (range: 0=no relief to 6=complete relief); Moderate relief is defined as STRRS = 3).

Time frame:
12 hours
Reported as:
Number · subjects
Sore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 12 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100 mg / PlaceboCelecoxib 100mg / 50mgPlacebo
Sore Throat Relief Rating Scale (STRRS) - 'Moderate Relief' at 12 Hours Post-First Dose21131214
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.202 (Treatment as a factor) · Odds ratio (or): 1.63 · 95% CI 0.8 to 3.5
  • Celecoxib 100 mg / Placebo vs Placebo · Regression, Logistic · p = 0.077 (Treatment as a factor) · Odds ratio (or): 2.18 · 95% CI 0.9 to 5.1
  • Celecoxib 100mg / 50mg vs Placebo · Regression, Logistic · p = 0.134 (Treatment as a factor) · Odds ratio (or): 1.95 · 95% CI 0.8 to 4.7
  • Celecoxib 50mg/50mg vs Celecoxib 100mg / 50mg · Regression, Logistic · p = 0.671 (Treatment as a factor) · Odds ratio (or): 0.84 · 95% CI 0.4 to 1.9
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo · Regression, Logistic · p = 0.484 (Treatment as a factor) · Odds ratio (or): 0.75 · 95% CI 0.3 to 1.7
  • Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg · Regression, Logistic · p = 0.814 (Treatment as a factor) · Odds ratio (or): 1.12 · 95% CI 0.4 to 2.8
SecondaryTime to Perceptible Pain Relief

Defined as time (measured by stopwatch) when subject began to feel any pain relieving effect from the drug

Time frame:
Within 2 Hours Post-First Dose
Reported as:
Median · minutes
Time to Perceptible Pain Relief
minutesCelecoxib 50mg/50mgCelecoxib 100 mg (Pooled)Placebo
Time to Perceptible Pain Relief49 (45 to 61)61 (46 to 75)97 (62 to 120)
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Log Rank · p = <0.05 (p-value for distribution of time to perceptible pain relief)
  • Celecoxib 100 mg (Pooled) vs Placebo · Log Rank · p = <0.05 (p-value for distribution of time to perceptible pain relief)
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) · Log Rank · p = <0.05 (p-value for distribution of time to perceptible pain relief)
SecondaryTime to Meaningful Pain Relief

The time (measured by stopwatch) when the subject felt their pain relief was meaningful to them was not estimable thus the number of subjects experiencing meaningful pain relief within 2 hours of first dose is reported

Time frame:
Within 2 Hours Post-First Dose
Reported as:
Number · subjects
Time to Meaningful Pain Relief
subjectsCelecoxib 50mg/50mgCelecoxib 100 mg (Pooled)Placebo
Time to Meaningful Pain Relief36 (NA to NA)33 (NA to NA)15 (NA to NA)
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Log Rank · p = <0.05 (p-value for distribution of time to meaningful pain relief)
  • Celecoxib 100 mg (Pooled) vs Placebo · Log Rank · p = <0.05 (p-value for distribution of time to meaningful pain relief)
SecondaryTime to Onset of Analgesia

Equal to time of perceptible pain relief when both perceptible pain relief and meaningful pain relief were experienced- the median time was not estimable thus the number of subjects with onset of analgesia within 2 hours of first dose is reported

Time frame:
Within 2 Hours Post-First Dose
Reported as:
Number · subjects
Time to Onset of Analgesia
subjectsCelecoxib 50mg/50mgCelecoxib 100 mg (Pooled)Placebo
Time to Onset of Analgesia36 (NA to NA)34 (NA to NA)15 (NA to NA)
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Log Rank · p = <0.05 (p-value for distribution of time to onset of analgesia)
  • Celecoxib 100 mg (Pooled) vs Placebo · Log Rank · p = <0.05 (p-value for distribution of time to onset of analgesia)
SecondaryPatient's Global Evaluation of Study Medication at 6 Hours Post-First Dose

Subject assessment of overall impression of study drug on 4 point scale from 1 (poor) to 4 (excellent)

Time frame:
6 Hours Post-First Dose
Reported as:
Number · subjects
Patient's Global Evaluation of Study Medication at 6 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100 mg (Pooled)Placebo
Excellent (4)542
Good (3)24255
Fair (2)252722
Poor (1)353360
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Mantel Haenszel · p = <0.001 (Overall test of Celecoxib 50mg/50mg versus Placebo that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 100 mg (Pooled) vs Placebo · Mantel Haenszel · p = <0.001 (Overall test of Celecoxib 100mg (pooled) versus Placebo that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg (Pooled) · Mantel Haenszel · p = 0.889 (Overall test of Celecoxib 50mg/50mg versus Celecoxib 100mg (pooled) that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
SecondaryPatient's Global Evaluation of Study Medication at 12 and 24 Hours Post-First Dose

Subject assessment of overall impression of study drug on 4 point scale from 1 (poor) to 4 (excellent)

Time frame:
12 and 24 hours Post-First Dose
Reported as:
Number · subjects
Patient's Global Evaluation of Study Medication at 12 and 24 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100 mg / PlaceboCelecoxib 100mg / 50mgPlacebo
Excellent (4) - 12 hours8501
Good (3) - 12 hours23101310
Fair (2) - 12 hours21111118
Poor (1) - 12 hours37182056
Excellent (4) - 24 hours7422
Good (3) - 24 hours2013913
Fair (2) - 24 hours2571515
Poor (1) - 24 hours37211857
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Mantel Haenszel · p = <0.001 (Analysis at 12 hours Overall test of Celecoxib 50mg/50mg versus Placebo that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 100 mg / Placebo vs Placebo · Mantel Haenszel · p = 0.002 (Analysis at 12 hours Overall test of Celecoxib 100mg/Placebo versus Placebo that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 100mg / 50mg vs Placebo · Mantel Haenszel · p = 0.015 (Analysis at 12 hours Overall test of Celecoxib 100mg/50mg versus Placebo that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 50mg/50mg vs Celecoxib 100mg / 50mg · Mantel Haenszel · p = 0.411 (Analysis at 12 hours Overall test of Celecoxib 50mg/50mg versus Celecoxib 100mg/50mg that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo · Mantel Haenszel · p = 0.930 (Analysis at 12 hours Overall test of Celecoxib 50mg/50mg versus Celecoxib 100mg/Placebo that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg · Mantel Haenszel · p = 0.438 (Analysis at 12 hours Overall test of Celecoxib 100mg/Placebo versus Celecoxib 100mg/50mg that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 50mg/50mg vs Placebo · Mantel Haenszel · p = 0.002 (Analysis at 24 hours Overall test of Celecoxib 50mg/50mg versus Placebo that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 100 mg / Placebo vs Placebo · Mantel Haenszel · p = 0.013 (Analysis at 24 hours Overall test of Celecoxib 100mg/Placebo versus Placebo that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 100mg / 50mg vs Placebo · Mantel Haenszel · p = 0.015 (Analysis at 24 hours Overall test of Celecoxib 100mg/50mg versus Placebo that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 50mg/50mg vs Celecoxib 100mg / 50mg · Mantel Haenszel · p = 0.748 (Analysis at 24 hours Overall test of Celecoxib 50mg/50mg versus Celecoxib 100mg/50mg that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 50mg/50mg vs Celecoxib 100 mg / Placebo · Mantel Haenszel · p = 0.958 (Analysis at 24 hours Overall test of Celecoxib 50mg/50mg versus Celecoxib 100mg/Placebo that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
  • Celecoxib 100 mg / Placebo vs Celecoxib 100mg / 50mg · Mantel Haenszel · p = 0.747 (Analysis at 24 hours Overall test of Celecoxib 100mg/Placebo versus Celecoxib 100mg/50mg that takes into account the ordered data (categories: excellent, good, fair, poor).)Test of row mean score differences based on modified ridits (standardizing the mid-rank)
Other pre-specifiedThroat Soreness Scale (TSS) Difference Within 6 Hours Post-First Dose

The Pain Intensity Difference (PID) based on TSS (scale: 0=not sore to 10=very sore) was calculated as the difference between the pain intensity at the time and at baseline.

Time frame:
Within first 6 hours post-first dose
Reported as:
Least squares mean · scores on a scale
Throat Soreness Scale (TSS) Difference Within 6 Hours Post-First Dose
scores on a scaleCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
15 min0.06 ± 0.040.06 ± 0.040.06 ± 0.04
30 min0.39 ± 0.080.36 ± 0.080.29 ± 0.08
45 min0.74 ± 0.100.66 ± 0.100.43 ± 0.10
60 min1.17 ± 0.130.97 ± 0.130.60 ± 0.13
75 min1.62 ± 0.151.29 ± 0.150.75 ± 0.15
90 min1.97 ± 0.171.64 ± 0.170.76 ± 0.17
1.75 hours2.24 ± 0.181.86 ± 0.180.79 ± 0.19
2 hours2.39 ± 0.192.03 ± 0.190.78 ± 0.19
3 hours2.43 ± 0.202.09 ± 0.200.85 ± 0.21
4 hours2.14 ± 0.212.12 ± 0.211.01 ± 0.21
5 hours2.03 ± 0.202.06 ± 0.211.04 ± 0.21
6 hours1.83 ± 0.201.90 ± 0.200.90 ± 0.21
Statistical analysis
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.999 (Analysis at 15 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.609 (Analysis at 30 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.076 (Analysis at 45 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.008 (Analysis at 60 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 75 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 90 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 1.75 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 2 hours Overall P-value)Continuous data were analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 3 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 4 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 5 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.001 (Analysis at 6 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedThroat Soreness Scale (TSS) Difference From 7 to 24 Hours Post-First Dose

The Pain Intensity Difference (PID) based on TSS (scale: 0=not sore to 10=very sore) was calculated as the difference between the pain intensity at the time and at baseline.

Time frame:
7 to 24 hours post-first dose
Reported as:
Least squares mean · scores on a scale
Throat Soreness Scale (TSS) Difference From 7 to 24 Hours Post-First Dose
scores on a scaleCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
7 hours1.65 ± 0.211.95 ± 0.301.68 ± 0.290.78 ± 0.21
8 hours1.67 ± 0.211.65 ± 0.301.70 ± 0.300.76 ± 0.22
9 hours1.76 ± 0.221.60 ± 0.321.65 ± 0.320.90 ± 0.23
10 hours1.80 ± 0.231.58 ± 0.331.63 ± 0.320.87 ± 0.23
11 hours1.76 ± 0.231.53 ± 0.321.76 ± 0.320.87 ± 0.23
12 hours1.53 ± 0.231.37 ± 0.331.80 ± 0.330.82 ± 0.24
24 hours1.62 ± 0.251.46 ± 0.361.78 ± 0.351.17 ± 0.25
Statistical analysis
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.003 (Analysis at 7 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.009 (Analysis at 8 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.043 (Analysis at 9 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.032 (Analysis at 10 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.029 (Analysis at 11 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.066 (Analysis at 12 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.482 (Analysis at 24 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedSore Throat Pain Intensity Difference (SPID2) as Measured by Throat Soreness Scale (TSS) at 2 Hours Post-First Dose

SPID2 was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS scale: 0=not sore to 10=very sore) at 2 hours post dose and at baseline.

Time frame:
2 hour period Post-First Dose
Reported as:
Least squares mean · units on a scale * hours
Sore Throat Pain Intensity Difference (SPID2) as Measured by Throat Soreness Scale (TSS) at 2 Hours Post-First Dose
units on a scale * hoursCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
Sore Throat Pain Intensity Difference (SPID2) as Measured by Throat Soreness Scale (TSS) at 2 Hours Post-First Dose2.4 ± 0.212.0 ± 0.211.0 ± 0.21
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 1.3 · 95% CI 0.8 to 1.9Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.002 (Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 0.9 · 95% CI 0.4 to 1.5Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.186 (Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): -0.4 · 95% CI -1.0 to 0.2Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedSum of Throat Soreness Difference as Measured by Throat Soreness Scale (TSS) Within 6 Hours Post-First Dose

The sum of sore throat pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS range: 0=not sore to 10=very sore) at the time and at baseline.

Time frame:
Within 6 hours Post-First Dose
Reported as:
Least squares mean · units on a scale * hours
Sum of Throat Soreness Difference as Measured by Throat Soreness Scale (TSS) Within 6 Hours Post-First Dose
units on a scale * hoursCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
15 min0.01 ± 0.010.01 ± 0.010.01 ± 0.01
30 min0.07 ± 0.020.06 ± 0.020.05 ± 0.02
45 min0.21 ± 0.030.19 ± 0.030.14 ± 0.04
60 min0.45 ± 0.060.39 ± 0.060.27 ± 0.06
75 min0.80 ± 0.090.67 ± 0.090.44 ± 0.09
90 min1.24 ± 0.131.04 ± 0.130.63 ± 0.13
1.75 hours1.77 ± 0.161.48 ± 0.160.82 ± 0.17
2 hours2.35 ± 0.211.96 ± 0.211.02 ± 0.21
3 hours4.76 ± 0.394.02 ± 0.391.83 ± 0.39
4 hours7.05 ± 0.586.12 ± 0.582.76 ± 0.59
5 hours9.13 ± 0.768.21 ± 0.773.79 ± 0.77
6 hours11.07 ± 0.9410.20 ± 0.944.75 ± 0.95
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.961 (Analysis at 15 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.985 (Analysis at 15 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.975 (Analysis at 15 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.532 (Analysis at 30 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.690 (Analysis at 30 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.820 (Analysis at 30 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.180 (Analysis at 45 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.344 (Analysis at 45 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.693 (Analysis at 45 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.039 (Analysis at 60 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.154 (Analysis at 60 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.521 (Analysis at 60 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.006 (Analysis at 75 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.070 (Analysis at 75 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.344 (Analysis at 75 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.001 (Analysis at 90 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.022 (Analysis at 90 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.249 (Analysis at 90 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 1.75 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.006 (Analysis at 1.75 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.205 (Analysis at 1.75 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.002 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.186 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 3 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 3 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.179 (Analysis at 3 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 4 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 4 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.259 (Analysis at 4 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 5 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 5 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.393 (Analysis at 5 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.512 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedSum of Throat Soreness Difference as Measured by Throat Soreness Scale (TSS) From 7 to 24 Hours Post-First Dose

The sum of sore throat pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Sore Throat PID was calculated as the difference between the pain intensity (TSS range: 0=not sore to 10=very sore) at the time and at baseline.

Time frame:
7 to 24 hours Post-First Dose
Reported as:
Least squares mean · units on a scale * hours
Sum of Throat Soreness Difference as Measured by Throat Soreness Scale (TSS) From 7 to 24 Hours Post-First Dose
units on a scale * hoursCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
7 hours12.8 ± 1.114.2 ± 1.69.9 ± 1.65.6 ± 1.1
8 hours14.5 ± 1.316.0 ± 1.811.6 ± 1.86.3 ± 1.3
9 hours16.2 ± 1.517.7 ± 2.113.3 ± 2.17.2 ± 1.5
10 hours18.0 ± 1.719.3 ± 2.414.9 ± 2.38.1 ± 1.7
11 hours19.7 ± 1.820.8 ± 2.616.6 ± 2.68.9 ± 1.9
12 hours21.4 ± 2.022.3 ± 2.918.4 ± 2.99.8 ± 2.1
24 hours40.3 ± 4.539.2 ± 6.439.8 ± 6.421.7 ± 4.6
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.026 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.463 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.131 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.053 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.020 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.484 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.197 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.086 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.018 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.561 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.252 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.136 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.018 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.653 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.287 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.191 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.018 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.741 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.326 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.256 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = 0.001 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.016 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.808 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.394 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.343 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.005 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = 0.029 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.023 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.892 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.952 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.948 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedDifficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) Within 6 Hours Post-First Dose

The Difficulty Swallowing Pain Intensity Difference (PID) was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.

Time frame:
Within 6 hours Post-First Dose
Reported as:
Least squares mean · units on a scale
Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) Within 6 Hours Post-First Dose
units on a scaleCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
15 min1.69 ± 0.891.16 ± 0.890.81 ± 0.89
30 min4.85 ± 1.213.14 ± 1.211.11 ± 1.21
45 min6.99 ± 1.435.75 ± 1.432.85 ± 1.44
60 min11.21 ± 1.658.02 ± 1.653.53 ± 1.66
75 min14.31 ± 1.8410.47 ± 1.843.95 ± 1.85
90 min17.40 ± 1.9912.21 ± 1.993.97 ± 2.00
1.75 hours20.52 ± 2.1115.15 ± 2.114.45 ± 2.12
2 hours21.76 ± 2.2516.50 ± 2.254.99 ± 2.26
3 hours22.20 ± 2.1718.39 ± 2.174.20 ± 2.18
4 hours20.53 ± 2.3318.27 ± 2.337.28 ± 2.34
5 hours18.40 ± 2.3118.11 ± 2.316.02 ± 2.32
6 hours16.62 ± 2.2716.43 ± 2.275.70 ± 2.29
Statistical analysis
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.775 (Analysis at 15 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.094 (Analysis at 30 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.114 (Analysis at 45 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.005 (Analysis at 60 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 75 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 90 min Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 1.75 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 2 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 3 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 4 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 5 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.001 (Analysis at 6 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedDifficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) From 7 to 24 Hours Post-First Dose

The Difficulty Swallowing Pain Intensity Difference (PID) was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.

Time frame:
7 to 24 hours Post-First Dose
Reported as:
Least squares mean · units on a scale
Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) From 7 to 24 Hours Post-First Dose
units on a scaleCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
7 hours16.91 ± 2.3518.11 ± 3.3211.38 ± 3.324.86 ± 2.36
8 hours16.53 ± 2.3817.29 ± 3.3713.40 ± 3.374.88 ± 2.39
9 hours16.59 ± 2.3515.10 ± 3.3212.68 ± 3.325.46 ± 2.36
10 hours16.61 ± 2.3914.32 ± 3.3811.68 ± 3.385.85 ± 2.41
11 hours15.01 ± 2.4512.99 ± 3.4613.13 ± 3.465.22 ± 2.46
12 hours15.40 ± 2.5111.44 ± 3.5513.41 ± 3.555.30 ± 2.53
24 hours14.25 ± 2.7013.67 ± 3.8313.24 ± 3.828.79 ± 2.72
Statistical analysis
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.001 (Analysis at 7 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.002 (Analysis at 8 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.007 (Analysis at 9 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.015 (Analysis at 10 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.033 (Analysis at 11 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.036 (Analysis at 12 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.500 (Analysis at 24 hours Overall P-value)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedSum of Sore Throat Pain Intensity Difference (SPID2) as Measured by Difficulty Swallowing Scale (DSS) at 2 Hours Post-First Dose

SPID2 was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 2 hours post dose and at baseline.

Time frame:
Over 2 hour Period Post-First Dose
Reported as:
Least squares mean · units on a scale * hours
Sum of Sore Throat Pain Intensity Difference (SPID2) as Measured by Difficulty Swallowing Scale (DSS) at 2 Hours Post-First Dose
units on a scale * hoursCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
Sum of Sore Throat Pain Intensity Difference (SPID2) as Measured by Difficulty Swallowing Scale (DSS) at 2 Hours Post-First Dose22.0 ± 2.7316.0 ± 2.735.8 ± 2.75
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 16.2 · 95% CI 8.5 to 23.8Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.009 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 10.2 · 95% CI 2.6 to 17.9Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.127 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): -5.9 · 95% CI -13.5 to 1.7Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedSum of Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) Within 6 Hours Post-First Dose

The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.

Time frame:
Within 6 hours Post-First Dose
Reported as:
Least squares mean · units on a scale * hours
Sum of Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) Within 6 Hours Post-First Dose
units on a scale * hoursCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
15 min0.2 ± 0.10.1 ± 0.10.1 ± 0.1
30 min1.0 ± 0.30.7 ± 0.30.3 ± 0.3
45 min2.5 ± 0.61.8 ± 0.60.8 ± 0.6
60 min4.8 ± 1.03.5 ± 1.01.6 ± 1.0
75 min8.0 ± 1.45.8 ± 1.42.6 ± 1.4
90 min11.9 ± 1.88.7 ± 1.83.6 ± 1.8
1.75 hours16.7 ± 2.212.1 ± 2.24.6 ± 2.3
2 hours22.0 ± 2.716.0 ± 2.75.8 ± 2.8
3 hours43.9 ± 4.833.5 ± 4.810.4 ± 4.8
4 hours65.3 ± 6.851.8 ± 6.816.1 ± 6.9
5 hours84.8 ± 9.070.0 ± 9.022.8 ± 9.0
6 hours102.3 ± 11.087.3 ± 11.028.6 ± 11.1
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.480 (Analysis at 15 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.780 (Analysis at 15 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.667 (Analysis at 15 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.153 (Analysis at 30 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.479 (Analysis at 30 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.469 (Analysis at 30 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.062 (Analysis at 45 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.284 (Analysis at 45 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.421 (Analysis at 45 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.022 (Analysis at 60 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.171 (Analysis at 60 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.354 (Analysis at 60 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.005 (Analysis at 75 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.090 (Analysis at 75 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.262 (Analysis at 75 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.001 (Analysis at 90 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.044 (Analysis at 90 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.194 (Analysis at 90 min Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 1.75 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.020 (Analysis at 1.75 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.148 (Analysis at 1.75 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.009 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.127 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 3 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.001 (Analysis at 3 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.122 (Analysis at 3 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 4 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 4 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.164 (Analysis at 4 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 5 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 5 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.244 (Analysis at 5 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.336 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedSum of Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) From 7 to 24 Hours Post-First Dose

The sum of pain intensity differences (SPID) was calculated as the AUC of the Pain Intensity Difference (PID) scores. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS range: 0mm=not difficult, 100mm=very difficult) at the time and at baseline.

Time frame:
7 to 24 hours Post-First Dose
Reported as:
Least squares mean · units on a scale * hours
Sum of Difficulty Swallowing Difference as Measured by Difficulty Swallowing Scale (DSS) From 7 to 24 Hours Post-First Dose
units on a scale * hoursCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
7 hours119.1 ± 13.0133.6 ± 18.372.2 ± 18.333.9 ± 13.0
8 hours135.8 ± 15.0151.3 ± 21.384.5 ± 21.338.8 ± 15.1
9 hours152.3 ± 17.1167.5 ± 24.297.6 ± 24.243.9 ± 17.2
10 hours168.9 ± 19.1182.2 ± 27.0109.8 ± 27.049.6 ± 19.2
11 hours184.7 ± 21.1195.8 ± 29.9122.2 ± 29.955.1 ± 21.3
12 hours200.0 ± 23.2208.0 ± 32.8135.4 ± 32.860.4 ± 23.4
24 hours377.9 ± 50.4358.7 ± 71.3295.3 ± 71.3144.9 ± 50.7
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.090 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.518 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.038 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.019 (Analysis at 7 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.081 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.552 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.050 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.027 (Analysis at 8 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.071 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.609 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.065 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.042 (Analysis at 9 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.070 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.689 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.075 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Continuous data were analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.059 (Analysis at 10 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.069 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.762 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.089 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.083 (Analysis at 11 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.064 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.841 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.110 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.119 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.001 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Placebo · Generalized linear model · p = 0.015 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.087 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Generalized linear model · p = 0.826 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.345 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.530 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.)Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedDifficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 6 Hours Post-First Dose

Number of Subjects with \>= 50% Pain Intensity Difference (PID) on the DSS. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 6 hours and at baseline.

Time frame:
At 6 hours
Reported as:
Number · subjects
Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 6 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 6 Hours Post-First Dose222414
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.149 · Odds ratio (or): 1.73 · 95% CI 0.8 to 3.7Treatment as a factor
  • Celecoxib 100mg (Pooled) vs Placebo · Regression, Logistic · p = 0.076 · Odds ratio (or): 1.95 · 95% CI 0.9 to 4.1Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Regression, Logistic · p = 0.733 · Odds ratio (or): 1.12 · 95% CI 0.6 to 2.2Treatment as a factor
Other pre-specifiedDifficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 12 Hours Post-First Dose

Number of Subjects with \>= 50% Pain Intensity Difference (PID) on the DSS. The Difficulty Swallowing PID was calculated as the difference between the pain intensity (DSS scale: 0mm=not difficult, 100mm=very difficult) at 12 hours and at baseline.

Time frame:
At 12 Hours
Reported as:
Number · subjects
Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 12 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
Difficulty Swallowing Scale (DSS) Difference at Least 50% Gone at 12 Hours Post-First Dose24121012
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.030 · Odds ratio (or): 2.33 · 95% CI 1.1 to 5.0Treatment as a factor
  • Celecoxib 100mg/Placebo vs Placebo · Regression, Logistic · p = 0.064 · Odds ratio (or): 2.33 · 95% CI 1.0 to 5.7Treatment as a factor
  • Celecoxib 100mg/50mg vs Placebo · Regression, Logistic · p = 0.201 · Odds ratio (or): 1.83 · 95% CI 0.7 to 4.6Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.575 · Odds ratio (or): 1.27 · 95% CI 0.5 to 3.0Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Regression, Logistic · p = 1.000 · Odds ratio (or): 1.00 · 95% CI 0.4 to 2.2Treatment as a factor
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.624 · Odds ratio (or): 1.27 · 95% CI 0.5 to 3.3Treatment as a factor
Other pre-specifiedTotal Pain Relief (TOTPAR) at 2 and 6 Hours Post-First Dose

TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief).

Time frame:
2 and 6 hours Post-First Dose
Reported as:
Least squares mean · scores on a scale
Total Pain Relief (TOTPAR) at 2 and 6 Hours Post-First Dose
scores on a scaleCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
2 hours2.6 ± 0.22.2 ± 0.21.3 ± 0.2
6 hours10.6 ± 0.89.9 ± 0.85.3 ± 0.8
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 1.28 · 95% CI 0.7 to 1.9Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = 0.003 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 0.88 · 95% CI 0.3 to 1.5Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.177 (Analysis at 2 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): -0.40 · 95% CI -1.0 to 0.2Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 5.25 · 95% CI 3.0 to 7.5Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg (Pooled) vs Placebo · Generalized linear model · p = <0.001 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 4.54 · 95% CI 2.3 to 6.8Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Generalized linear model · p = 0.531 (Analysis at 6 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): -0.72 · 95% CI -3.0 to 1.5Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedTotal Pain Relief (TOTPAR) at 12 and 24 Hours Post-First Dose

TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief).

Time frame:
12 and 24 hours Post-First Dose
Reported as:
Least squares mean · scores on a scale
Total Pain Relief (TOTPAR) at 12 and 24 Hours Post-First Dose
scores on a scaleCelecoxib 50mg/50mgCelecoxib 100mg /PlaceboCelecoxib 100mg/50mgPlacebo
12 hours20.6 ± 1.722.0 ± 2.417.5 ± 2.411.6 ± 1.7
24 hours40.9 ± 3.641.5 ± 5.136.7 ± 5.127.3 ± 3.7
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 9.07 · 95% CI 4.4 to 13.7Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg /Placebo vs Placebo · Generalized linear model · p = <0.001 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 10.46 · 95% CI 4.7 to 16.2Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.041 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 5.96 · 95% CI 0.2 to 11.7Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg /Placebo · Generalized linear model · p = 0.633 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): -1.39 · 95% CI -7.1 to 4.3Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.284 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 3.11 · 95% CI -2.6 to 8.8Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg /Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.180 (Analysis at 12 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 4.50 · 95% CI -2.1 to 11.1Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.009 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 13.57 · 95% CI 3.4 to 23.7Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg /Placebo vs Placebo · Generalized linear model · p = 0.026 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 14.15 · 95% CI 1.7 to 26.6Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.138 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 9.39 · 95% CI -3.0 to 21.8Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg /Placebo · Generalized linear model · p = 0.926 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): -0.59 · 95% CI -13.0 to 11.8Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.507 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 4.18 · 95% CI -8.2 to 16.6Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
  • Celecoxib 100mg /Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.513 (Analysis at 24 hours Pairwise comparison. No adjustment made for multiplicity.) · Mean difference (final values): 4.77 · 95% CI -9.6 to 19.1Analyzed using a Generalized Linear Model with treatment as fixed effect and baseline score as a covariate
Other pre-specifiedSubjects With >= 50% Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose

TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief). Maximum TOTPAR over 6 hours is 36. If the subject calculated TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject is said to have achieved \>=50% TOTPAR.

Time frame:
6 hours Post-First Dose
Reported as:
Number · subjects
Subjects With >= 50% Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
Subjects With >= 50% Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose18197
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.023 · Odds ratio (or): 2.93 · 95% CI 1.2 to 7.4Treatment as a factor
  • Celecoxib 100mg (Pooled) vs Placebo · Regression, Logistic · p = 0.015 · Odds ratio (or): 3.13 · 95% CI 1.2 to 7.9Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Regression, Logistic · p = 0.854 · Odds ratio (or): 1.07 · 95% CI 0.5 to 2.2Treatment as a factor
Other pre-specifiedSubjects With >= 50% Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose

TOTPAR is time-interval-weighted sum of accumulated Sore Throat Relief Rating Scale (STRRS) scores (scale: 0 no relief to 6 complete relief). Maximum TOTPAR over 12 hours is 72. If the subject calculated TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject is said to have achieved \>=50% TOTPAR.

Time frame:
12 hours Post-First Dose
Reported as:
Number · subjects
Subjects With >= 50% Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
Subjects With >= 50% Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose181286
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.013 · Odds ratio (or): 3.46 · 95% CI 1.3 to 9.2Treatment as a factor
  • Celecoxib 100mg/Placebo vs Placebo · Regression, Logistic · p = 0.003 · Odds ratio (or): 5.03 · 95% CI 1.7 to 14.5Treatment as a factor
  • Celecoxib 100mg/50mg vs Placebo · Regression, Logistic · p = 0.057 · Odds ratio (or): 2.99 · 95% CI 1.0 to 9.2Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.758 · Odds ratio (or): 1.16 · 95% CI 0.5 to 2.9Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Regression, Logistic · p = 0.381 · Odds ratio (or): 0.69 · 95% CI 0.3 to 1.6Treatment as a factor
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.313 · Mean difference (final values): 1.68 · 95% CI 0.6 to 4.6Treatment as a factor
Other pre-specifiedNumber Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose

NNT is number of subjects needed to treat to have one extra subject report a 50% or better pain relief over 6 hours based on maximum possible pain relief on Sore Throat Relief Rating Scale. Maximum TOTPAR over 6 hours is 36. If the subject TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject has achieved \>=50% TOTPAR.

Time frame:
6 hours Post-First Dose
Reported as:
Number · subjects
Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 6 Hours Post-First Dose18197
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Nnt at 6 hours: 8.2 · 95% CI 4.5 to 46.4
  • Celecoxib 100mg (Pooled) vs Placebo · Nnt at 6 hours: 7.5 · 95% CI 4.3 to 32.0
Other pre-specifiedNumber Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose

NNT is number of subjects needed to treat to have one subject report a 50% or better pain relief over 12 hours based on maximum possible pain relief on Sore Throat Relief Rating Scale. Maximum TOTPAR over 12 hours is 72. If the subject TOTPAR is greater than or equal to 50% of the maximum TOTPAR then the subject has achieved \>=50% TOTPAR.

Time frame:
12 hours Post-First Dose
Reported as:
Number · subjects
Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
Number Needed to Treat (NNT) to Achieve at Least 50% of Maximum Total Pain Relief (TOTPAR) at 12 Hours Post-First Dose181286
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Nnt at 12 hours: 7.5 · 95% CI 4.3 to 28.7
  • Celecoxib 100mg/Placebo vs Placebo · Nnt at 12 hours: 5.0 · 95% CI 3.0 to 16.7
Other pre-specifiedSubjects With Sore Throat Pain at Least 35% Gone and at Least 50% Gone at 2 and 6 Hours Post-First Dose

\>= 35% and 50% Pain Intensity Difference (PID) on the Pain Intensity-Visual Analog Scale (PI-VAS) (scale: 0mm=no pain, 100mm=worst possible pain). The PID was calculated as the difference between the pain intensity at the time and at baseline.

Time frame:
2 and 6 hours Post-First Dose
Reported as:
Number · subjects
Subjects With Sore Throat Pain at Least 35% Gone and at Least 50% Gone at 2 and 6 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
2 hours >=35% gone393215
6 hours >=35% gone312912
2 hours >=50% gone28248
6 hours >=50% gone23229
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = <0.001 (Analysis for 2 hours \>=35% gone) · Odds ratio (or): 3.77 · 95% CI 1.9 to 7.6Treatment as a factor
  • Celecoxib 100mg (Pooled) vs Placebo · Regression, Logistic · p = 0.005 (Analysis for 2 hours \>=35% gone) · Odds ratio (or): 2.72 · 95% CI 1.3 to 5.5Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Regression, Logistic · p = 0.286 (Analysis for 2 hours \>=35% gone) · Odds ratio (or): 0.72 · 95% CI 0.4 to 1.3Treatment as a factor
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.001 (Analysis for 6 hours \>=35% gone) · Odds ratio (or): 3.37 · 95% CI 1.6 to 7.1Treatment as a factor
  • Celecoxib 100mg (Pooled) vs Placebo · Regression, Logistic · p = 0.004 (Analysis for 6 hours \>=35% gone) · Odds ratio (or): 3.05 · 95% CI 1.4 to 6.5Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Regression, Logistic · p = 0.752 (Analysis for 6 hours \>=35% gone) · Odds ratio (or): 0.90 · 95% CI 0.5 to 1.7Treatment as a factor
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = <0.001 (Analysis for 2 hours \>=50% gone) · Odds ratio (or): 4.57 · 95% CI 1.9 to 10.7Treatment as a factor
  • Celecoxib 100mg (Pooled) vs Placebo · Regression, Logistic · p = 0.003 (Analysis for 2 hours \>=50% gone) · Odds ratio (or): 3.68 · 95% CI 1.6 to 8.7Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Regression, Logistic · p = 0.511 (Analysis for 2 hours \>=50% gone) · Odds ratio (or): 0.81 · 95% CI 0.4 to 1.5Treatment as a factor
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.009 (Analysis for 6 hours \>=50% gone) · Odds ratio (or): 3.05 · 95% CI 1.3 to 7.0Treatment as a factor
  • Celecoxib 100mg (Pooled) vs Placebo · Regression, Logistic · p = 0.014 (Analysis for 6 hours \>=50% gone) · Odds ratio (or): 2.88 · 95% CI 1.2 to 6.7Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Regression, Logistic · p = 0.863 (Analysis for 6 hours \>=50% gone) · Odds ratio (or): 0.94 · 95% CI 0.5 to 1.9Treatment as a factor
Other pre-specifiedSubjects With Sore Throat Pain at Least 35% Gone and at Least 50% Gone at 12 Hours Post-First Dose

\>= 35% and 50% Pain Intensity Difference (PID) on the Pain Intensity-Visual Analog Scale (PI-VAS) (scale: 0mm=no pain, 100mm=worst possible pain). The PID was calculated as the difference between the pain intensity at 12 hours and at baseline.

Time frame:
12 hours Post-First Dose
Reported as:
Number · subjects
Subjects With Sore Throat Pain at Least 35% Gone and at Least 50% Gone at 12 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
12 hours >=35% gone30131213
12 hours >=50% gone2212109
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.004 (12 hours \>=35% gone) · Odds ratio (or): 2.92 · 95% CI 1.4 to 6.1Treatment as a factor
  • Celecoxib 100mg/Placebo vs Placebo · Regression, Logistic · p = 0.052 (12 hours \>=35% gone) · Odds ratio (or): 2.37 · 95% CI 1.0 to 5.7Treatment as a factor
  • Celecoxib 100mg/50mg vs Placebo · Regression, Logistic · p = 0.095 (12 hours \>=35% gone) · Odds ratio (or): 2.13 · 95% CI 0.9 to 5.1Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.431 (12 hours \>=35% gone) · Odds ratio (or): 1.38 · 95% CI 0.6 to 3.0Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Regression, Logistic · p = 0.602 (12 hours \>=35% gone) · Odds ratio (or): 1.23 · 95% CI 0.6 to 2.7Treatment as a factor
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.814 (12 hours \>=35% gone) · Odds ratio (or): 1.12 · 95% CI 0.4 to 2.8Treatment as a factor
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.014 (12 hours \>=50% gone) · Odds ratio (or): 2.88 · 95% CI 1.2 to 6.7Treatment as a factor
  • Celecoxib 100mg/Placebo vs Placebo · Regression, Logistic · p = 0.016 (12 hours \>=50% gone) · Odds ratio (or): 3.23 · 95% CI 1.2 to 8.4Treatment as a factor
  • Celecoxib 100mg/50mg vs Placebo · Regression, Logistic · p = 0.063 (12 hours \>=50% gone) · Odds ratio (or): 2.54 · 95% CI 0.9 to 6.8Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.775 (12 hours \>=50% gone) · Odds ratio (or): 1.13 · 95% CI 0.5 to 2.7Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Regression, Logistic · p = 0.779 (12 hours \>=50% gone) · Odds ratio (or): 0.89 · 95% CI 0.4 to 2.0Treatment as a factor
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.624 (12 hours \>=50% gone) · Odds ratio (or): 1.27 · 95% CI 0.5 to 3.3Treatment as a factor
Other pre-specifiedSubjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 2 and 6 Hours Post-First Dose

Symptom relief measured as self-directed endpoints defined by each individual at end of study using Sore Throat Relief Rating Scale (STRRS); STRRS score ranges from 0=no relief to 6=complete relief. If subject scored same or greater in their STRRS during the study then they achieved their 'Meaningful Relief' or 'Much Improvement'.

Time frame:
2 and 6 hours Post-First Dose
Reported as:
Number · subjects
Subjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 2 and 6 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
meaningful relief - 2 hours- achieved312612
meaningful relief- 2 hours- not achieved596377
meaningful relief - 6 hours- achieved403817
meaningful relief- 6 hours- not achieved505172
much improvement - 2 hours- achieved222210
much improvement - 2 hours- not achieved686779
much improvement - 6 hours- achieved333112
much improvement - 6 hours- not achieved575877
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.001 (Analysis for meaningful Relief at 2 hours)Treatment as a factor
  • Celecoxib 100mg (Pooled) vs Placebo · Regression, Logistic · p = 0.012 (Analysis for meaningful Relief at 2 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Regression, Logistic · p = 0.453 (Analysis for meaningful Relief at 2 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = <0.001 (Analysis for meaningful Relief at 6 hours)Treatment as a factor
  • Celecoxib 100mg (Pooled) vs Placebo · Regression, Logistic · p = 0.001 (Analysis for meaningful Relief at 6 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Regression, Logistic · p = 0.814 (Analysis for meaningful Relief at 6 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.024 (Analysis for Much Improvement at 2 hours)Treatment as a factor
  • Celecoxib 100mg (Pooled) vs Placebo · Regression, Logistic · p = 0.022 (Analysis for Much Improvement at 2 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Regression, Logistic · p = 0.966 (Analysis for Much Improvement at 2 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.001 (Analysis for Much Improvement at 6 hours)Treatment as a factor
  • Celecoxib 100mg (Pooled) vs Placebo · Regression, Logistic · p = 0.001 (Analysis for Much Improvement at 6 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Regression, Logistic · p = 0.798 (Analysis for Much Improvement at 6 hours)Treatment as a factor
Other pre-specifiedSubjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 12 Hours Post-First Dose

Symptom relief measured as self-directed endpoints defined by each individual at end of study using Sore Throat Relief Rating Scale (STRRS); STRRS score ranges from 0=no relief to 6=complete relief. If subject scored same or greater in their STRRS during the study then they achieved their 'Meaningful Relief' or 'Much Improvement'.

Time frame:
12 hours Post-First Dose
Reported as:
Number · subjects
Subjects Who Achieved Their Own Level of 'Meaningful Relief' and 'Much Improvement' at 12 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100mg /PlaceboCelecoxib 100mg/50mgPlacebo
Meaningful Relief - achieved44262020
Meaningful Relief - not achieved46192469
Much Improvement - achieved38221216
Much Improvement - not achieved52233273
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = <0.001 (Analysis for Meaningful Relief)Treatment as a factor
  • Celecoxib 100mg /Placebo vs Placebo · Regression, Logistic · p = <0.001 (Analysis for Meaningful Relief)Treatment as a factor
  • Celecoxib 100mg/50mg vs Placebo · Regression, Logistic · p = 0.008 (Analysis for Meaningful Relief)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.709 (Analysis for Meaningful Relief)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg /Placebo · Regression, Logistic · p = 0.331 (Analysis for Meaningful Relief)Treatment as a factor
  • Celecoxib 100mg /Placebo vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.246 (Analysis for Meaningful Relief)Treatment as a factor
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.001 (Analysis for Much Improvement)Treatment as a factor
  • Celecoxib 100mg /Placebo vs Placebo · Regression, Logistic · p = <0.001 (Analysis for Much Improvement)Treatment as a factor
  • Celecoxib 100mg/50mg vs Placebo · Regression, Logistic · p = 0.219 (Analysis for Much Improvement)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.095 (Analysis for Much Improvement)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg /Placebo · Regression, Logistic · p = 0.463 (Analysis for Much Improvement)Treatment as a factor
  • Celecoxib 100mg /Placebo vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.038 (Analysis for Much Improvement)Treatment as a factor
Other pre-specifiedSubjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Who Had Perceptible Relief Onset Time Within 1 Hour

At end of study subjects defined meaningful pain relief by completing Meaningful Relief Scale. Meaningful relief was achieved if Sore Throat Relief Rating Scale (STRRS) score (range: 0=no relief to 6=complete relief) at end of the study was the same or higher than individually defined relief score during the study. Perceptible relief is STRRS \>0.

Time frame:
Within 6 hours Post-First Dose
Reported as:
Number · subjects
Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Who Had Perceptible Relief Onset Time Within 1 Hour
subjectsCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
Achieved312712
Not achieved596277
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.001Treatment as a factor
  • Celecoxib 100mg (Pooled) vs Placebo · Regression, Logistic · p = 0.008Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg (Pooled) · Regression, Logistic · p = 0.557Treatment as a factor
Other pre-specifiedSubjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Who Still Had Perceptible Relief at 12 and 24 Hours Post-First Dose

At end of study subjects defined meaningful pain relief by completing the Meaningful Relief Scale. Meaningful relief was achieved if Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief) score at end of the study was the same or higher than individually defined relief score during the study. Perceptible relief is STRRS \>0

Time frame:
12 and 24 hours Post-First Dose
Reported as:
Number · subjects
Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Who Still Had Perceptible Relief at 12 and 24 Hours Post-First Dose
subjectsCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
at 12 hours - Achieved32161211
at 12 hours - Not Achieved58293278
at 24 hours - Achieved2816911
at 24 hours - Not Achieved62293578
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = <0.001 (Analysis at 12 hours)Treatment as a factor
  • Celecoxib 100mg/Placebo vs Placebo · Regression, Logistic · p = 0.002 (Analysis at 12 hours)Treatment as a factor
  • Celecoxib 100mg/50mg vs Placebo · Regression, Logistic · p = 0.036 (Analysis at 12 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.339 (Analysis at 12 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Regression, Logistic · p = 1.000 (Analysis at 12 hours)Treatment as a factor
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.401 (Analysis at 12 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.003 (Analysis at 24 hours)Treatment as a factor
  • Celecoxib 100mg/Placebo vs Placebo · Regression, Logistic · p = 0.002 (Analysis at 24 hours)Treatment as a factor
  • Celecoxib 100mg/50mg vs Placebo · Regression, Logistic · p = 0.223 (Analysis at 24 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.198 (Analysis at 24 hours)Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Regression, Logistic · p = 0.604 (Analysis at 24 hours)Treatment as a factor
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.117 (Analysis at 24 hours)Treatment as a factor
Other pre-specifiedMedian Onset Time of First Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose

Perceptible Relief is score \>0 on STRRS. Individual level of meaningful relief had to be reached within 6 hours. Meaningful Relief was achieved if Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief)score at the end of the study was the same or higher than individually defined meaningful relief score during the study.

Time frame:
24 Hours
Reported as:
Median · hours
Median Onset Time of First Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose
hoursCelecoxib 50mg/50mgCelecoxib 100mg (Pooled)Placebo
Median Onset Time of First Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose0.75 (0.25 to 3.00)0.63 (0.25 to 1.50)0.50 (0.25 to 6.00)
Other pre-specifiedMedian Offset Time of No Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose

Offset time is time of first no perceptible relief (STRRS score=0) with meaningful relief (score\>0) at earlier time. STRRS score ranges from 0=no relief to 6=complete relief.

Time frame:
24 Hours
Reported as:
Median · hours
Median Offset Time of No Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose
hoursCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
Median Offset Time of No Perceptible Relief in Subjects Who Achieved Their Own Level of 'Meaningful Relief' Within 6 Hours Post-First Dose8.00 (3.00 to 24.00)8.00 (1.25 to 9.00)8.00 (3.00 to 24.00)10.00 (2.00 to 12.00)
Other pre-specifiedTreatment Failures on STRRS Questionnaire

Subjects were considered treatment failures if all of the STRRS scores were less than each individual's 'meaningful relief' scores. STRRS score ranges from 0=no relief to 6=complete relief.

Time frame:
24 hours Post-First Dose
Reported as:
Number · subjects
Treatment Failures on STRRS Questionnaire
subjectsCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
Not treatment failures46272023
Treatment failures44182466
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.001Treatment as a factor
  • Celecoxib 100mg/Placebo vs Placebo · Regression, Logistic · p = <0.001Treatment as a factor
  • Celecoxib 100mg/50mg vs Placebo · Regression, Logistic · p = 0.025Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.539Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Regression, Logistic · p = 0.329Treatment as a factor
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.171Treatment as a factor
Other pre-specifiedSubjects Taking Rescue Medication

Subjects were allowed to use rescue medication at any time during the trial, but were discouraged from taking rescue medication within 2 hours of administration of the first dose of study drug.

Time frame:
Within 24 hours Post-First Dose
Reported as:
Number · subjects
Subjects Taking Rescue Medication
subjectsCelecoxib 50mg/50mgCelecoxib 100mg /PlaceboCelecoxib 100mg/50mgPlacebo
Subjects Taking Rescue Medication22151339
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Regression, Logistic · p = 0.007Treatment as a factor
  • Celecoxib 100mg /Placebo vs Placebo · Regression, Logistic · p = 0.244Treatment as a factor
  • Celecoxib 100mg/50mg vs Placebo · Regression, Logistic · p = 0.096Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.579Treatment as a factor
  • Celecoxib 50mg/50mg vs Celecoxib 100mg /Placebo · Regression, Logistic · p = 0.277Treatment as a factor
  • Celecoxib 100mg /Placebo vs Celecoxib 100mg/50mg · Regression, Logistic · p = 0.649Treatment as a factor
Other pre-specifiedTreatment Satisfaction Questionnaire for Medication (TSQM vII)

11 questions scored on factors: effectiveness, side effects, convenience, overall satisfaction. TSQM vII scores range 0 to 100, with higher scores indicating a higher level of global satisfaction with treatment.

Time frame:
24 hours or immediately prior to taking rescue medication
Reported as:
Mean · scores on a scale
Treatment Satisfaction Questionnaire for Medication (TSQM vII)
scores on a scaleCelecoxib 50mg/50mgCelecoxib 100mg /PlaceboCelecoxib 100mg/50mgPlacebo
Effectiveness41.5 ± 26.640.6 ± 28.734.3 ± 26.226.1 ± 25.4
Side Effects96.3 ± 12.096.7 ± 11.697.9 ± 9.798.6 ± 8.2
Convenience77.2 ± 15.173.0 ± 17.469.3 ± 16.871.3 ± 14.6
Global Satisfaction49.1 ± 28.047.8 ± 33.442.2 ± 30.636.0 ± 27.3
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = <0.001 (Analysis of Effectiveness) · Mean difference (final values): 15.4 · 95% CI 7.5 to 23.2Treatment as a fixed effect
  • Celecoxib 100mg /Placebo vs Placebo · Generalized linear model · p = 0.003 (Analysis of Effectiveness) · Mean difference (final values): 14.4 · 95% CI 4.9 to 24.0Treatment as a fixed effect
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.096 (Analysis of Effectiveness) · Mean difference (final values): 8.2 · 95% CI -1.5 to 17.8Treatment as a fixed effect
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.141 (Analysis of Effectiveness) · Mean difference (final values): 7.2 · 95% CI -2.4 to 16.8Treatment as a fixed effect
  • Celecoxib 50mg/50mg vs Celecoxib 100mg /Placebo · Generalized linear model · p = 0.849 (Analysis of Effectiveness) · Mean difference (final values): 0.9 · 95% CI -8.6 to 10.5Treatment as a fixed effect
  • Celecoxib 100mg /Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.266 (Analysis of Effectiveness) · Mean difference (final values): 6.3 · 95% CI -4.8 to 17.4Treatment as a fixed effect
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.141 (Analysis of Side Effects) · Mean difference (final values): -2.3 · 95% CI -5.4 to 0.8Treatment as a fixed effect
  • Celecoxib 100mg /Placebo vs Placebo · Generalized linear model · p = 0.312 (Analysis of Side Effects) · Mean difference (final values): -1.9 · 95% CI -5.7 to 1.8Treatment as a fixed effect
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.724 (Analysis of Side Effects) · Mean difference (final values): -0.7 · 95% CI -4.5 to 3.1Treatment as a fixed effect
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.398 (Analysis of Side Effects) · Mean difference (final values): -1.6 · 95% CI -5.4 to 2.1Treatment as a fixed effect
  • Celecoxib 50mg/50mg vs Celecoxib 100mg /Placebo · Generalized linear model · p = 0.846 (Analysis of Side Effects) · Mean difference (final values): -0.4 · 95% CI -4.1 to 3.4Treatment as a fixed effect
  • Celecoxib 100mg /Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.572 (Analysis of Side Effects) · Mean difference (final values): -1.3 · 95% CI -5.6 to 3.1Treatment as a fixed effect
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.014 (Analysis of Convenience) · Mean difference (final values): 5.8 · 95% CI 1.2 to 10.4Treatment as a fixed effect
  • Celecoxib 100mg /Placebo vs Placebo · Generalized linear model · p = 0.573 (Analysis of Convenience) · Mean difference (final values): 1.6 · 95% CI -4.0 to 7.2Treatment as a fixed effect
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.482 (Analysis of Convenience) · Mean difference (final values): -2.0 · 95% CI -7.7 to 3.6Treatment as a fixed effect
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.007 (Analysis of Convenience) · Mean difference (final values): 7.8 · 95% CI 2.2 to 13.5Treatment as a fixed effect
  • Celecoxib 50mg/50mg vs Celecoxib 100mg /Placebo · Generalized linear model · p = 0.143 (Analysis of Convenience) · Mean difference (final values): 4.2 · 95% CI -1.4 to 9.8Treatment as a fixed effect
  • Celecoxib 100mg /Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.273 (Analysis of Convenience) · Mean difference (final values): 3.6 · 95% CI -2.9 to 10.2Treatment as a fixed effect
  • Celecoxib 50mg/50mg vs Placebo · Generalized linear model · p = 0.003 (Analysis of Global Satisfaction) · Mean difference (final values): 13.0 · 95% CI 4.4 to 21.6Treatment as a fixed effect
  • Celecoxib 100mg /Placebo vs Placebo · Generalized linear model · p = 0.029 (Analysis of Global Satisfaction) · Mean difference (final values): 11.7 · 95% CI 1.2 to 22.2Treatment as a fixed effect
  • Celecoxib 100mg/50mg vs Placebo · Generalized linear model · p = 0.251 (Analysis of Global Satisfaction) · Mean difference (final values): 6.2 · 95% CI -4.4 to 16.8Treatment as a fixed effect
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.204 (Analysis of Global Satisfaction) · Mean difference (final values): 6.8 · 95% CI -3.7 to 17.4Treatment as a fixed effect
  • Celecoxib 50mg/50mg vs Celecoxib 100mg /Placebo · Generalized linear model · p = 0.808 (Analysis of Global Satisfaction) · Mean difference (final values): 1.3 · 95% CI -9.2 to 11.8Treatment as a fixed effect
  • Celecoxib 100mg /Placebo vs Celecoxib 100mg/50mg · Generalized linear model · p = 0.371 (Analysis of Global Satisfaction) · Mean difference (final values): 5.5 · 95% CI -6.6 to 17.7Treatment as a fixed effect
Other pre-specifiedFirst Perceptible Relief

Subjects having First Perceptible Relief at each time point. Perceptible relief is score \>0 on Sore Throat Relief Rating Scale(STRRS)(range: 0=no relief to 6=complete relief).

Time frame:
up to 24 hours
Reported as:
Number · subjects
First Perceptible Relief
subjectsCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
1 hour - Onset subjects in hour68292240
1 hour - No onset subjects in hour22162349
2 hour - Onset subjects in hour1310911
2 hour-No onset subjects in hour961438
3 hour - Onset subjects in hour1202
3 hour-No onset subjects in hour841436
4 hour - Onset subjects in hour0024
4 hour- No onset subjects in hour841232
5 hour - Onset subjects in hour0014
5 hour-No onset subjects in hour841128
6 hour - Onset subjects in hour0131
6 hour-No onset subjects in hour83827
7 hour - Onset subjects in hour0011
7 hour-No onset subjects in hour83726
8 hour - Onset subjects in hour0012
8 hour-No onset subjects in hour83624
9 hour - Onset subjects in hour2002
9 hour-No onset subjects in hour63622
10 hour - Onset subjects in hour0000
10 hour-No onset subjects in hour63622
11 hour - Onset subjects in hour0001
11 hour-No onset subjects in hour (63621
12 hour - Onset subjects in hour0001
12 hour-No onset subjects in hour63620
24 hour - Onset subjects in hour1002
24 hour-No onset subjects in hour53618
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Mantel Haenszel · p = <0.001 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)
  • Celecoxib 100mg/Placebo vs Placebo · Mantel Haenszel · p = 0.002 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)
  • Celecoxib 100mg/50mg vs Placebo · Mantel Haenszel · p = 0.235 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Mantel Haenszel · p = 0.012 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Mantel Haenszel · p = 0.438 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Mantel Haenszel · p = 0.067 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)
Other pre-specifiedNo Perceptible Relief

Subjects having No Perceptible Relief at each time point. No Perceptible relief is score = 0 on Sore Throat Relief Rating Scale (STRRS)(range: 0=no relief to 6=complete relief).

Time frame:
up to 24 hours
Reported as:
Number · subjects
No Perceptible Relief
subjectsCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
1 hour - Offset subjects in hour0000
1 hour-No offset subjects in hour90454589
2 hour- Offset subjects in hour0101
2 hour-No offset subjects in hr90444588
3 hour- Offset subjects in hour1010
3 hour-No offset subjects in hr89444488
4 hour- Offset subjects in hour0000
4 hour-No offset subjects in hr89444488
5 hour- Offset subjects in hour1000
5 hour-No offset subjects in hr88444488
6 hour- Offset subjects in hour0001
6 hour-No offset subjects in hr88444487
7 hour- Offset subjects in hour4221
7 hour-No offset subjects in hr84424286
8 hour- Offset subjects in hour1200
8 hour-No offset subjects in hr83404286
9 hour- Offset subjects in hour1310
9 hour-No offset subjects in hr82374186
10 hour-Offset subjects in hour2003
10 hour-No offset subjects in hr80374183
11 hour-Offset subjects in hour1000
11 hour-No offset subjects in hr79374183
12 hour-Offset subjects in hour1002
12 hour-No offset subjects in hr78374181
24 hour-Offset subjects in hour (N=78,37, 41, 81)3030
24 hour-No offset subjects in hr (N=78,37,41, 81)75373881
Statistical analysis
  • Celecoxib 50mg/50mg vs Placebo · Mantel Haenszel · p = 0.128 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)
  • Celecoxib 100mg/Placebo vs Placebo · Mantel Haenszel · p = 0.123 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)
  • Celecoxib 100mg/50mg vs Placebo · Mantel Haenszel · p = 0.266 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/50mg · Mantel Haenszel · p = 0.849 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)
  • Celecoxib 50mg/50mg vs Celecoxib 100mg/Placebo · Mantel Haenszel · p = 0.828 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)
  • Celecoxib 100mg/Placebo vs Celecoxib 100mg/50mg · Mantel Haenszel · p = 0.741 (Based on life-table extension of Mantel-Haenszel method. p-value for general association)

Adverse events

Collected over Baseline (Day 1) up to 28 days after last dose of study drug ( up to a maximum of 30 days). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib 50mg/50mg0/90 (0%)0/90 (0%)8/90 (8.9%)
Celecoxib 100mg/Placebo0/45 (0%)0/45 (0%)5/45 (11.1%)
Celecoxib 100mg/50mg0/45 (0%)0/45 (0%)5/45 (11.1%)
Placebo0/89 (0%)0/89 (0%)6/89 (6.7%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCelecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlacebo
NauseaGastrointestinal disorders3/902/450/451/89
DyspepsiaGastrointestinal disorders0/900/450/452/89
ConjunctivitisEye disorders1/900/451/451/89
FatigueGeneral disorders1/901/450/450/89
Otitis mediaInfections and infestations0/900/451/451/89
DizzinessNervous system disorders2/900/450/451/89
HeadacheNervous system disorders2/900/450/450/89
WheezingRespiratory, thoracic and mediastinal disorders0/900/451/451/89
Rash generalizedSkin and subcutaneous tissue disorders0/901/451/450/89
Abdominal distensionGastrointestinal disorders0/901/450/450/89

Baseline characteristics

Age, Continuous
Age, Continuous(years)Celecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlaceboTotal
Mean19.5 ± 1.319.6 ± 1.419.9 ± 2.319.3 ± 1.419.5 ± 1.5
Sex: Female, Male
Sex: Female, Male(Participants)Celecoxib 50mg/50mgCelecoxib 100mg/PlaceboCelecoxib 100mg/50mgPlaceboTotal
Female55251549144
Male35203040125
08

Study locations

1 site
  • University of Connecticut Student Health Services
    Storrs, Connecticut 06269-2011, United States
09

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2006 to primary completion in Nov 2007, 11 months.

Results were first posted in Mar 2009, 1 year 3 months after primary completion.

Of 13 phase 3 interventional studies under Pharyngitis, half reached primary completion within 3 months of starting (the median); a quarter within 2 and three quarters within 6. This study's 11 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2006
First posted
Nov 23, 2006
StartActual
Dec 4, 2006
Primary completionActual
Nov 15, 2007
CompletionActual
Nov 15, 2007
Results first posted
Mar 12, 2009
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00402987
Responsible party
Sponsor
First posted
Nov 23, 2006
Start date
Dec 4, 2006
Primary completion
Nov 15, 2007
Completion
Nov 15, 2007
Results posted
Mar 12, 2009
Last update
Mar 3, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion